ArticleTheranostics2017
Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Advances in Engineering Human Tissue Models.Frontiers in bioengineering and biotechnology · 2020Pooled it
- 3D bioprinting for the production of a perfusable vascularized model of a cancer niche.Frontiers in bioengineering and biotechnology · 2025Article
- Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model.Cancers · 2024Article
- Microfluidic model of the alternative vasculature in neuroblastoma.In vitro models · 2024Article
- Review
- SOX2-positive retinal stem cells are identified in adult human pars plicata by single-cell transcriptomic analyses.MedComm · 2023Article
- Clinicopathological significance of vasculogenic mimicry and fetal hemoglobin expression in peripheral neuroblastic tumors in children.American journal of translational research · 2023Article
- A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Tumor-on-a-chip: Perfusable vascular incorporation brings new approach to tumor metastasis research and drug development.Frontiers in bioengineering and biotechnology · 2022Review
- Long non-coding RNA NHEG1/hsa-miR-665/HMGB1 axis is involved in the regulation of neuroblastoma progression.Bioengineered · 2021Article
- Microphysiological systems to study tumor-stroma interactions in brain cancer.Brain research bulletin · 2021Review
- Fundamental Technologies and Recent Advances of Cell-Sheet-Based Tissue Engineering.International journal of molecular sciences · 2021Review
- The Angiotensin-Converting Enzyme Inhibitory State Promotes the Transformation of Non-Small Cell Lung Cancer Blood Supply Pattern Toward Vasculogenic Mimicry Formation.Frontiers in oncology · 2021Article
- Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.Theranostics · 2020Article
- Emerging Neuroblastoma 3DFrontiers in immunology · 2020Review
- Developing preclinical models of neuroblastoma: driving therapeutic testing.BMC biomedical engineering · 2019Review
- Modeling human bladder cancer.World journal of urology · 2018Review
- Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development.Cell stem cell · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Neuroblastoma is a vascularized pediatric tumor derived from neural crest stem cells that displays vasculogenic mimicry and can express a number of stemness markers, such as SOX2 and NANOG. Tumor relapse is the major cause of succumbing to this disease, and properties attributed to cancer stem-like cells (CSLC), such as drug-resistance and cell plasticity, seem to be the key mechanisms. However, the lack of controllable models that recapitulate the features of human neuroblastoma limits our understanding of the process and impedes the development of new therapies. In response to these limitations, we engineered a perfusable, vascularized
methodsThe
resultsThe bioengineered model recapitulated vasculogenic mimicry (vessel-like structure formation and tumor-derived endothelial cells-TECs), and contained CSLC expressing SOX2 and NANOG. Treatment with Isotretinoin destabilized vascular networks but failed to target vasculogenic mimicry and augmented populations of CSLCs expressing high levels of SOX2. Our results suggest that CSLCs can transdifferentiate into drug resistant CD31
conclusionOur results reveal some roles of SOX2 in drug resistance and tumor relapse, and suggest that SOX2 could be a therapeutic target in neuroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.